Sangamo Therapeutics filed for Chapter 11 bankruptcy protection and agreed to sell major parts of its gene editing platforms and select programs through two stalking-horse asset sale agreements. Eli Lilly is set to acquire Sangamo’s capsid delivery, ZFN, and MINT platforms plus the prion disease program ST-506. Astellas will take over Sangamo’s Fabry disease program isaralgagene civaparvovec (ST-920). Sangamo said other assets, including its ST-503 chronic neuropathic pain program and certain cell therapy assets, are not included in the stalking-horse bids and would remain available for sale at auction. Sangamo characterized the process as a value-maximizing transaction framework while seeking to support stakeholders. The company said the deals do not include its clinical-stage programs outside the specified assets, and it expects those excluded programs to continue to be offered to other interested bidders. The Chapter 11 filing closes a more than three-decade gene editing track record without an approved therapy from Sangamo itself, underscoring how platform-heavy biotechs can struggle to translate clinical signals into durable financial runway.